![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAQR7 |
Gene summary for PAQR7 |
![]() |
Gene information | Species | Human | Gene symbol | PAQR7 | Gene ID | 164091 |
Gene name | progestin and adipoQ receptor family member 7 | |
Gene Alias | MPRA | |
Cytomap | 1p36.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86WK9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
164091 | PAQR7 | C04 | Human | Oral cavity | OSCC | 1.43e-02 | 2.21e-01 | 0.2633 |
164091 | PAQR7 | C30 | Human | Oral cavity | OSCC | 3.78e-15 | 1.01e+00 | 0.3055 |
164091 | PAQR7 | C51 | Human | Oral cavity | OSCC | 3.16e-04 | 5.44e-01 | 0.2674 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:007138318 | Oral cavity | OSCC | cellular response to steroid hormone stimulus | 112/7305 | 204/18723 | 2.82e-06 | 3.47e-05 | 112 |
GO:004340116 | Oral cavity | OSCC | steroid hormone mediated signaling pathway | 76/7305 | 136/18723 | 4.76e-05 | 3.99e-04 | 76 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAQR7 | SNV | Missense_Mutation | novel | c.344N>A | p.Phe115Tyr | p.F115Y | Q86WK9 | protein_coding | deleterious(0) | possibly_damaging(0.741) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PAQR7 | SNV | Missense_Mutation | rs763250786 | c.4N>A | p.Ala2Thr | p.A2T | Q86WK9 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
PAQR7 | SNV | Missense_Mutation | rs749730710 | c.857N>T | p.Thr286Met | p.T286M | Q86WK9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
PAQR7 | SNV | Missense_Mutation | c.433N>T | p.Gly145Trp | p.G145W | Q86WK9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F4-6855-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PAQR7 | SNV | Missense_Mutation | rs371961113 | c.671N>A | p.Arg224His | p.R224H | Q86WK9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PAQR7 | SNV | Missense_Mutation | novel | c.155N>T | p.Arg52Leu | p.R52L | Q86WK9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAQR7 | SNV | Missense_Mutation | novel | c.121N>T | p.Leu41Phe | p.L41F | Q86WK9 | protein_coding | tolerated(0.11) | possibly_damaging(0.723) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAQR7 | SNV | Missense_Mutation | novel | c.269C>T | p.Ala90Val | p.A90V | Q86WK9 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PAQR7 | SNV | Missense_Mutation | rs750969371 | c.146C>T | p.Ala49Val | p.A49V | Q86WK9 | protein_coding | tolerated(0.22) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAQR7 | SNV | Missense_Mutation | rs757157861 | c.643N>A | p.Ala215Thr | p.A215T | Q86WK9 | protein_coding | tolerated(0.32) | benign(0.284) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |